window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical Trials

  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics

    From outputs to outcomes: Saama’s Derek Lawrence on why clinical data management must change

    Clinical data management is under pressure to evolve as trials [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

    Syngene International has extended its strategic collaboration with Bristol Myers [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth

    Veristat, a global clinical research organization (CRO) and consultancy specializing [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bicara announces Phase 3 optimal dose for ficerafusp alfa and provides 2026 corporate outlook

    Bicara Therapeutics has selected 1500 mg of ficerafusp alfa as [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Manufacturing & Supply Chain

    FDA clears IND amendment for automated manufacturing of Cabaletta’s rese-cel using Cellares platforms

    Cellares has secured FDA clearance of an IND amendment allowing [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Breast cancer tops list of most-studied diseases for fifth consecutive year, Phesi analysis finds

    Breast cancer remained the world’s most studied disease for the [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    Trialbee secures majority investment from Varsity Healthcare Partners to scale patient recruitment

    Trialbee has secured a majority growth investment from Varsity Healthcare [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Opinion & Events

    Like the ten leaping Lords, PHARMASEAL takes a leap towards smarter growth in 2026

    With the lords a-leaping, the industry is set to spring [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Opinion & Events

    Nine ladies dancing: uMotif – patient-centric trials and AI take centre stage in 2026

    As part of Discover Pharma’s 12 days of Christmas series, [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data

    Six geese a-laying: CluePoints’ AI predictions for 2026

    As our Christmas countdown continues, we move from reflections on [...]

    May 5, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • EMA accepts Almirall application to extend Ebglyss use in young children with atopic dermatitis
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Ten-year NHS study supports focal therapy for prostate cancer with fewer side effects
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Mission Therapeutics signs US$292M deal for acute kidney injury programme
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top